Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Meiragtx Holdings Plc
(NQ:
MGTX
)
4.260
+0.080 (+1.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Meiragtx Holdings Plc
< Previous
1
2
3
Next >
MeiraGTx's Investigational Drug Shows Improved Symptoms In Radiation-Induced Oral Dryness
June 27, 2023
MeiraGTx Holdings plc (NASDAQ: MGTX) released data from the completed Phase 1 AQUAx study of AAV2-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX), which includes the final 12-month data from...
Via
Benzinga
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
June 27, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company’s Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,
June 22, 2023
From
MeiraGTx
Via
GlobeNewswire
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying
May 16, 2023
Although US stocks closed higher on Monday, there were a few notable insider trades.
Via
Benzinga
MeiraGTx Hldgs: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
MeiraGTx Holdings's Return On Capital Employed Overview
March 15, 2023
Via
Benzinga
MeiraGTx's Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms
December 13, 2022
Via
Benzinga
MeiraGTx Announces the Presentation of Nine Posters at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting
May 16, 2023
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports First Quarter 2023 Financial and Operational Results
May 11, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces $60 Million Private Placement of Ordinary Shares
May 03, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Posts Encouraging Gene Therapy Data From Eye Disorder Trial
June 28, 2022
Via
Benzinga
MeiraGTx Hldgs: Q1 Earnings Insights
May 12, 2022
MeiraGTx Hldgs (NASDAQ:MGTX) reported its Q1 earnings results on Thursday, May 12, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting
April 21, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
April 20, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results
March 14, 2023
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
December 13, 2022
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022
December 08, 2022
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
November 22, 2022
From
MeiraGTx
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
November 10, 2022
During Thursday's session, 97 companies made new 52-week lows.
Via
Benzinga
MeiraGTx Reports Third Quarter 2022 Financial and Operational Results and Receives $25 Million Investment from Johnson & Johnson Innovation - JJDC, Inc.
November 10, 2022
From
MeiraGTx
Via
GlobeNewswire
MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress
October 04, 2022
Multiple Poster Presentations Highlight Versatility and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell Therapy
From
MeiraGTx
Via
GlobeNewswire
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)
October 01, 2022
Results from the Phase 1/2 MGT009 study presented at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting set the stage for Phase 3 LUMEOS trial of botaretigene sparoparvovec in XLRP, which...
From
MeiraGTx
Via
GlobeNewswire
Kiora Pharma is Starting Human Trials of a Novel Treatment That Could Restore Vision In Patients With Inherited Blindness
September 29, 2022
Kiora Pharmaceuticals Inc. (NASDAQ: KPRX), a pharmaceutical company specializing in treating eye diseases, is moving its drug candidate KIO-301 into a Phase 1b study in the third quarter of this year.
Via
Benzinga
Why Poseida Therapeutics Is Trading Higher By Around 100%, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
August 03, 2022
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares jumped 167% to $1.72 after dropping 13% on Tuesday.
Via
Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
August 04, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.
Via
Benzinga
54 Biggest Movers From Yesterday
December 08, 2021
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and...
Via
Benzinga
MeiraGTx Reveals Interim Data From Phase 1 Trial Of Radiation-Induced Dry Mouth Symptom
December 07, 2021
MeiraGTx Holdings plc (NASDAQ: MGTX) has announced preliminary data from the ongoing Phase 1 AQUAx trial of AAV-hAQP1 for grade 2/3 radiation-induced xerostomia (...
Via
Benzinga
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
December 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Acadia Announces Positive Phase 3 Data For Trofinetide In Rett Syndrome...
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Looking for Growth in Small and Mid Cap Life Science Stocks
November 15, 2021
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.
Via
Talk Markets
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.